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Abstract
Background: Meta-analysis has demonstrated an exponential relationship between 2-hr postchallenge
hyperglycemia and coronary artery disease (CAD). Pulsatile hyperglycemia can acutely increase proinflammatory
cytokines by oxidative stress. We hypothesized that postchallenge proinflammatory and nitrosative responses after
75 g oral glucose tolerance tests (75 g-OGTT) might be associated with CAD in patients without previously
recognized type 2 diabetes mellitus (T2DM).
Methods: Serial changes of plasma glucose (PG), tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6) and
nitrotyrosine levels were analyzed during 75 g-OGTT in 120 patients (81 male; age 62 ± 11 years) before coronary
angiography. Patients were classified as normal (NGT; 42%), impaired (IGT; 34%) and diabetic (T2DM; 24%) glucose
tolerance by 75 g-OGTT.
Results: Postchallenge hyperglycemia elicited TNF-a, IL-6 and nitrotyrosine levels time-dependently, and 2-hr
median levels of TNF-a (7.1 versus 6.4 pg/ml; P < 0.05) and nitrotyrosine (1.01 versus 0.83 μmol/l; P < 0.05), but not
IL-6 or PG, were significantly higher in patients with CAD in either IGT or T2DM groups. After adjusting risk factors
and glucose tolerance status, 2-hr nitrotyrosine in highest quartiles (OR: 3.1, P < 0.05) remained an independent
predictor of CAD by logistic regression analysis.
Conclusions: These results highlight postchallenge proinflammatory and nitrosative responses by 75 g-OGTT,
rather than hyperglycemia per se, are associated with CAD in patients without previous recognized diabetes.
Keywords: Postchallenge hyperglycemia, Inflammation, Oxidative stress, Nitrotyrosine oral, Glucose tolerance test,
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Background
Type 2 diabetes mellitus (T2DM) is widely accepted as
an independent risk factor of atherosclerotic cardiovas-
cular diseases [1]. Meta-analysis has demonstrated an
exponential relationship between 2-hr postchallenge
hyperglycemia and cardiovascular risks, and this rela-
tionship might extend below the diabetic threshold [2].
Epidemiological studies have also shown that subjects
with impaired glucose tolerance (IGT) have a raised risk
of cardiovascular morbidity and mortality [3-6].
Chronic diabetic macrovascular complications might
be attributed to the exaggerated postprandial glycemic
excursion, rather than chronic fasting hyperglycemia [7].
Glycemic excursion promotes atherogenesis by several
possible mechanisms, including oxidative stress,
endothelial dysfunction, reduced nitric oxide bioavail-
ability, impaired vasodilation and formation of advanced
glycated end-products [8]. Postprandial “hyperglycemic
spike” is suggested to have impact on both endothelial
function and oxidative stress, and consequently, the
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enon is not only evident in patients with T2DM but
also extended into subjects with IGT [3,4]. However, the
question remains whether hyperglycemia is the marker
or the cause of atherosclerotic changes in patients with-
out overt T2DM [9,10].
Inflammation and oxidative stress elicited by either
hyperglycemia or hyperlipidemia play an interactive role
in the pathogenesis of insulin resistance, diabetes and
atherosclerosis [11-13]. Hyperglycemia spike had been
shown to acutely increase the levels of circulating proin-
flammatory cytokines, including tumor necrosis factor-
alpha (TNF-a) and interleukin-6 (IL-6), in subjects with
IGT and these responses are attenuated by antioxidant
[14]. In addition, pulsatile hyperglycemia increases these
cytokines to a greater extent than continuous hypergly-
cemia during similar glycemic levels [4,14]. Nitrotyro-
sine has been indirectly inferred as a marker of
postprandial oxidative stress because of the production
of peroxynitrite by acute hyperglycemia [14,15]. Experi-
mental study has revealed the presence of nitrotyrosine
from extensive nitration of protein tyrosine in human
coronary atherosclerotic lesions [16]. Clinically, correla-
tions between postprandial hyperglycemia and the gen-
eration of nitrotyrosine have been demonstrated in
patients with T2DM or gestational diabetic pregnancies
[16,17]. Moreover, elevated baseline nitrotyrosine levels
have recently been shown in association with coronary
artery disease (CAD) and modulated by statin therapy
[18]. However, it remains unknown whether the
dynamic changes of circulating TNF-a,I L - 6a n dn i t r o -
tyrosine induced by postchallenge hyperglycemia might
be associated with CAD in patients without previously
recognized T2DM.
We sought to investigate the dynamic responses of
circulating proinflammatory cytokines (TNF-a and IL-6)
and nitrosative stress (nitrotyrosine) induced by post-
challenge hyperglycemia after 75 g oral glucose toler-
ance test (75 g-OGTT) and to evaluate their
associations with the presence of CAD in patients with-
out previous diagnosed T2DM.
Methods
Patients enrollment
A total of 134 consecutive patients who underwent both
coronary arteriography and 75 g-OGTT test at Kaoh-
siung Medical University Hospital between April 2005
and May 2006 were enrolled. Seven patients were
excluded because of being treated for T2DM, having
fasting plasma glucose (PG) concentration ≧ 126 mg/dl
(7.0 mmol/l) or hemoglobin A1C ≧ 6.5% [19]. Another 7
patients with valvular heart disease, hypertrophic or
dilated cardiomyopathy, chronic renal insufficiency
(serum creatine > 2.0 mg/dl) or acute coronary events
within 6 months were also excluded. Thus, 120 patients
without previously overt T2DM were investigated pro-
spectively in this study. A standard questionnaire was
applied to all patients to acquire their personal medical
histories, traditional cardiovascular risk factors, symp-
toms of angina pectoris and current medication. All
patients underwent coronary arteriography because of
effort angina pectoris, positive exercise treadmill test or
positive stress myocardial perfusion scintigraphy. This
study complies with the Declaration of Helsinki, and the
study protocol was approved by the Institutional Review
Board at Kaohsiung Medical University and written
informed consents were obtained from all patients
75 g-OGTT and blood sampling
After a 12-hr overnight fast during hospital stay,
patients were asked to stay in a comfortable supine posi-
tion with a room temperature between 20° and 24°C.
Intravenous lines were inserted into a large antecubital
vein of one arm for blood sampling between 8 a.m. and
10 a.m. and patency was preserved by a slow saline infu-
sion (0.9% NaCl).
After the ingestion of a 75 g oral glucose, serial
venous blood samples (10 ml) for PG were collected
before (PG-0) and at 30 (PG-30), 60 (PG-60), 90 (PG-
90) and 120 (PG-120) minutes, and also for TNF-a,I L -
6 and nitrotyrosine at 0, 60 and 120 minutes. Blood
samples were collected into pyrogen-free vacuum collec-
tion tubes without additives for measurements of serum
TNF-a, IL-6, lipid profiles and hemoglobin A1C; or with
EDTA as anticoagulant for the measurement of PG and
nitrotyrosine. The blood collection tubes were immedi-
ately immersed in melting ice and centrifuged at 1500 g
for 10 min within 20 min (plasma) or allowed to clot
before centrifugation (serum). All samples were frozen
and stored at -80°C until analysis.
Biochemical measurements
PG concentrations were measured by the standard glu-
cose oxidase method. Total cholesterol and triglycerides
were determined by an enzymatic method. High-density
lipoprotein cholesterol (HDL-C) was measured after
phosphotungstic acid/MgCl2 precipitation on fresh
plasma. Low-density lipoprotein cholesterol (LDL-C)
was calculated using the Friedewald formula. The hemo-
globin A1C and fasting PG levels were analyzed by the
hospital central laboratory, with a normal hemoglobin
A1C reference range of 4.5 ~ 6.0%.
Enzyme immunoassays of TNF-a, IL-6 and nitrotyrosine
Serum levels of both TNF-a,I L - 6w e r em e a s u r e di n
duplicate by ELISA kits (R & D systems Inc., Minneapo-
lis, MN, USA) [14]. The concentrations of plasma nitro-
tyrosine were determined in duplicate by ELISA kits
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Canada) [17]. Dilution curves of analyzed samples were
parallel to those of standard. Intra-assay and interassay
coefficients of variation were 3.7% and 5.9%, respectively
for TNF-a; 3.8% and 5.6% respectively for IL-6; and
3.3% and 5.5% respectively for nitrotyrosine.
Coronary arteriography
Coronary arteriography followed after the 75 g-OGTT
was completed in each patient that same morning.
Patients were diagnosed to have CAD if coronary arter-
iography revealed any stenosed vessel with > 50% lumi-
nal narrowing by quantitative coronary analysis in the
main coronary arteries or major branches, otherwise
were non-CAD [20]. The numbers of stenosed or
occluded vessels were also calculated to define the clini-
cal (1- to 3-vessels disease) CAD score. The interpreta-
tions of all coronary arteriograms were done by three
observers who were blinded to the clinical and labora-
tory data. The interclass correlation coefficient for
intrarater reliability was 1.1 for the clinical CAD scores.
Glucose tolerance status
All patients were categorized by the final results of 75 g-
OGTT according to the diagnostic thresholds of the
Expert Committee on the Diagnosis and Classification
of Diabetes Mellitus [19]. Firstly, patients with fasting
PG < 100 mg/dl (5.6 mmol/l) and 100-125 mg/dl (5.6-
6.9 mmol/l) were considered to have normal and
impaired fasting glucose, respectively. Secondly, patients
with PG at 120 minutes < 140 mg/dl (7.8 mmol/l), 140-
199 mg/dl (7.8-11.0 mmol/l), and ≧ 200 mg/dl (11.1
mmol/l) were considered to have normal (NGT),
impaired (IGT), and diabetic GT (T2DM), respectively.
Patients with IGT or T2DM were considered to have
abnormal GT (AbnGT). Both status of GT and CAD
were taken into consideration for further subgroup
analysis.
Statistical analysis
Continuous variables were presented as mean (± SD)
where applicable. Levels of TNF-a,I L 6( b o t hi np g / m l )
and nitrotyrosine (in μmol/l) were not normally distrib-
uted and values were presented as median and inter-
quartile range. Categorical variables were compared by
chi-square analyses. Differences among groups were
examined by Kruskal-Wallis test followed by Mann-
Whitney U test with Bonferroni correction. Associations
were determined using the Pearson and Spearman cor-
relation coefficients for continuous measurements.
Logistic regression models were used to calculate odds
ratio (ORs) associated with the second, third, and the
highest quartile of TNF-a, IL-6 and nitrotyrosine,
respectively, and compared with the corresponding
lowest quartile for the presence of CAD. Trends were
assessed with Cochran-Armitage tests. All p values were
two-tailed and all confidence intervals were computed at
the 95% level. P value < 0.05 was considered statistically
significant. Statistical analysis was performed using SPSS
software version 11.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Baseline characteristics of patients categorized according
to the presence of CAD were summarized in Table 1. In
this study, patients with CAD were significantly older
and more likely to be male. No significant differences
were demonstrated between the CAD and non-CAD
groups with regards to systolic or diastolic blood
Table 1 Baseline characteristics of patients categorized
according to the presence of CAD (n = 120)
Characteristic CAD (n =
65)
Non-CAD (n =
55)
P
values
Age (yrs) 64.9 ± 10.6* 59.1 ± 9.6 < 0.05
Sex (F/M) 13/52* 26/29 < 0.05
SBP (mmHg) 132 ± 22 129 ± 19 0.238
DBP (mmHg) 81 ± 14 77 ± 12 0.163
Body mass index (kg/m
2) 26.6 ± 3.3 25.9 ± 4.8 0.835
Waist-to-hip ratio 0.85 ± 0.10 0.83 ± 0.15 0.729
Fasting plasma glucose (mg/
dl)
103.3 ± 12.3 101.7 ± 13.3 0.527
Impaired fasting glucose [n
(%)]
35 (53.9%) 30 (54.5%) 0.938
HbA1C (%) 5.4 ± 0.9 5.2 ± 0.7 0.725
Family history of CAD [n (%)] 12 (18.4%) 8 (14.5%) 0.815
Past history [n (%)]
Hypercholesterolemia 34 (52.3) 28 (51.0) 0.078
Hypertension 47 (72.3) 37 (67.2) 0.159
Alcohol intake 22 (33.8) 22 (40.0) 0.875
Current smoker 18 (27.7) 14 (25.4) 0.753
Lipid profiles (mg/dL)
Total cholesterol 215 ± 48 208 ± 41 0.238
LDL cholesterol 127 ± 37 119 ± 42 0.105
HDL cholesterol 41 ± 10 43 ± 12 0.369
Triglycerides 217 ± 126 209 ± 138 0.245
Concomitant medication [n
(%)]
Aspirin/Clopidogrel 37 (56.9) 25 (45.4) 0.095
b Adrenergic blockers 18 (27.7) 16 (29.1) 0.358
Calcium channel
blockers
44 (67.7) 36 (65.4) 0.259
ACE inhibitor/ARB 29 (44.6) 23 (41.8) 0.347
Diuretics 24 (36.9) 18 (32.7) 0.135
Statin 33 (50.8) 26 (47.2) 0.085
Fibrate 5 (7.7) 4 (7.3) 0.468
*P < 0.05; ACE = angiotensin-converting enzyme; ARB: angiotensin II receptor
blockers; BMI: body mass index; HbA1C: hemoglobin A1C; HDL: high density
lipoprotein; LDL: low density lipoprotein
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nificant differences in hemoglobin A1C,f a s t i n gg l u c o s e ,
lipid profiles or current medications can be shown
between the CAD and non-CAD groups in our study. In
terms of fasting glucose status, there were 55 (46%)
patients had normal fasting glucose and 65 (54%)
patients with impaired fasting glucose at baseline. How-
ever, no significant difference was found in the percen-
tage of impaired fasting glucose between the CAD and
non-CAD patients.
Glucose tolerance status and CAD
The proportions of patients with IGT (n = 41, 34%) and
T2DM (n = 29, 24%) documented after 75-g OGTT test
were relatively high, and less than half of our study sub-
jects had NGT (n = 50, 42%) (Figure 1A). Moreover,
subcategory analysis by fasting glucose status, there
were 47% had NGT, 40% had IGT, and 13% had T2DM
in patient with normal fasting glucose (n = 55), and
39%, 29% and 34%, correspondingly, in patient with
impaired fasting glucose (n = 65).
The frequency distributions of NGT, IGT and T2DM
among patients grouped by the presence of CAD and
number of stenosed coronary arteries were illustrated
(Figure 1B). The chi-square analyses revealed that
patients with IGT and T2DM were significantly asso-
ciated with the presence of CAD and the number of dis-
eased coronary arteries involved compared to patients
with NGT (both P values < 0.05). However, serial PG
levels during the entire course of 75 g-OGTT in patients
with NGT or AbnGT (IGT and T2DM) did not show
any significant difference in terms of the presence or
absence of CAD (Figure 1C). The time to peak PG
values tended to be later (at 60-90 minutes) in patients
with AbnGT than with NGT (at 30-60 minutes).
Responses of proinflammatory cytokines and
nitrotyrosine induced by postchallenge hyperglycemia
Serial changes of TNF-a, IL-6 and nitrotyrosine levels
after 75 g-OGTT at 0, 60 and 120 minutes among
patients with NGT, IGT, and T2DM (Figure 2A) and
between CAD and non-CAD patients (Figure 2B) were
Figure 1 The distributions of glucose tolerance (GT) and CAD status, as well as the PG response curve during 75 g-OGTT. (A) After 75
g OGTT, the proportions of IGT and T2DM are 34% and 24%, respectively.( B) Frequency distribution of GT status in the presence of CAD
or among the clinical (1- to 3- vessels diseases) scores. Significantly higher percentages of AbnGT (IGT and/or T2DM) are associated with CAD by
chi-square analysis (both P values < 0.05). The white, light grey and dark grey areas indicate the percentage of NGT, IGT and T2DM, respectively.
(C) No significant differences in PG response curves between CAD and non-CAD patients in either NGT or AbnGT group during the entire course
of 75 g-OGTT.
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ences in values of TNF-a, IL-6 or nitrotyrosine among 3
different glucose tolerance statuses or between CAD and
non-CAD groups. Circulating levels of TNF-a,I L - 6a n d
nitrotyrosine were consistently and time-dependently
elevated after postchallenge hyperglycemia. No signifi-
cant differences of postchallenge TNF-a, IL-6 and nitro-
tyrosine levels among patients with different GT status
could be shown. However, significant differences of both
TNF-a (7.1 [6.7-8.3]) versus 6.4 [5.8-7.9] pg/ml) and
nitrotyrosine (1.01 [0.82-1.17] versus 0.83 [0.74-1.01]
μmol/l) were able to be demonstrated at 2-hr after 75 g-
OGTT between CAD and non-CAD patients (both P
values < 0.05) (Figure 2 and Table 2). The differences of
IL-6 (5.2 [4.2-5.8] versus 4.8 [4.3-5.0] pg/ml) levels at 2-
hr after 75 g-OGTT load did not achieve significance
between CAD and non-CAD patients. However, for
patients with coronary 3-vessel diseases, significantly
higher levels of 2-hr IL-6 (5.4 [4.8-5.8] versus 4.8 [4.3-
5.0] pg/ml, p < 0.05) could be demonstrated in compari-
son with patients without CAD (Table 2).
The values of PG, TNF-a, IL-6 and nitrotyrosine cate-
gorized simultaneously with GT status and the presence
of CAD were summarized in Table 3. All the PG values
Figure 2 Postchallenge TNF-a, IL-6 and nitrotyrosine responses in (A) patients with different GT status or (B) patients with or without
CAD, after 75 g-OGTT. Circulating levels of TNF-a, IL-6 and nitrotyrosine are consistently and time-dependently elevated within 2-hr after 75 g-
OGTT. No significant differences of these cytokines levels among NGT, IGT or T2DM status are demonstrated. However, significant increases of
TNF-a and nitrotyrosine, but not IL-6, could be demonstrated at 120 minutes after 75 g-OGTT in CAD patients in comparison with non-CAD
patients. *P < 0.05.
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different between CAD and non-CAD patients in each
GT group separately. However, postchallenge TNF-a
and nitrotyrosine levels at 2-hr were both significantly
higher in either IGT or T2DM patients with CAD com-
pared to those without. Furthermore, when the status of
IGT plus T2DM were taken together into consideration
as AbnGT, both postchallenge TNF-a (7.8 [7.4-9.0] ver-
sus 6.4 [4.5-7.3] pg/ml) and nitrotyrosine (1.02 [0.92-
1.25] versus 0.81 [0.74-0.96] μmol/l) levels at 2-hr were
still able to be demonstrated in AbnGT patients with or
without CAD (both P values < 0.05) (Figure 3).
However, no significant differences of PG-120 or IL-6 at
2-hr could be found in CAD or non-CAD patients, in
either NGT or AbnGT groups. It was also noteworthy
that no such significant differences of postchallenge
TNF-a and nitrotyrosine at 2-hr could be demonstrated
in NGT patients with or without CAD.
Correlations of proinflammatory and nitrosative cytokines
and postchallenge hyperglycemia
Baseline TNF-a, IL-6 and nitrotyrosine levels did not
significantly correlate with baseline PG in this study.
However, after 75-g glucose challenge, significant
Table 2 Comparisons of plasma glucose, TNF-a, IL-6 and nitrotyrosine after 75 g OGTT at 120 minutes by the presence
of coronary artery disease and the number of significantly stenosed coronary arteries
Subgroup n PG-120 (mg/
dl)
p TNF-a (120) (pg/
ml)
p Post-
hoc
IL-6 (120) (pg/
ml)
p Post-
hoc
NT (120)
(μmo/l)
p Post-
hoc
CAD (-) 55 155 ± 60 0.063 6.4(5.8-7.9) <
0.05
4.8(4.3-5.0) 0.121 0.83(0.74-1.01) <
0.05
(+) 65 177 ± 56 7.1(6.7-8.3) 5.2(4.6-5.8) 1.01(0.82-1.17)
n-V-
D
(a) 0-v-d 55 155 ± 61 0.091 6.4(5.8-7.9) <
0.05
b > a 4.8(4.3-5.0) <
0.05
d > a 0.83(0.74-1.01) <
0.05
b>a
(b) 1-v-d 30 170 ± 46 7.3(5.7-7.8) c > a 5.2(4.4-5.5) 0.92(0.89-1.15) c > a
(c) 2-v-d 15 187 ± 59 6.9(6.3-7.8) d > a 5.1(4.5-5.4) 0.96(0.79-1.18) d > a
(d) 3-v-d 20 172 ± 57 7.4(6.6-8.8) 5.4(4.8-5.8) 0.99(0.82-1.25)
* By pair-t test or ANOVA with significant pairs from Turkey’s pairwise comparison. IL6: interleukin-6; NT: nitrotyrosine; PG: plasma glucose; TNF-a: tumor necrosis
factor-alpha; OGTT: oral glucose tolerance test
Table 3 Comparison of proinflammatory cytokines and oxidative markers before and after 75 g oral glucose tolerance
test (75 g-OGTT) in patients categorized according to glucose tolerance status and the presence of CAD
NGT (n = 50) IGT (n = 41) T2DM (n = 29)
CAD (n = 18) Non-CAD (n = 32) CAD (n = 28) Non-CAD (n = 13) CAD (n = 19) Non-CAD (n = 10)
PG (mg/dl)
PG-0 99 ± 11 98 ± 12 102 ± 11 100 ± 13 112 ± 13 108 ± 17
PG-30 163 ± 36 173 ± 43 175 ± 31 182 ± 13 203 ± 47 188 ± 34
PG-60 165 ± 44 165 ± 42 196 ± 38 204 ± 42 248 ± 60 216 ± 40
PG-90 152 ± 27 138 ± 28 187 ± 31 186 ± 21 257 ± 52 225 ± 43
PG-120 118 ± 15 112 ± 23 172 ± 17 170 ± 14 250 ± 51 246 ± 29
PG-150 114 ± 29 88 ± 23 148 ± 33 139 ± 19 204 ± 65 164 ± 57
PG-180 83 ± 26 85 ± 19 127 ± 40 104 ± 31 172 ± 69 167 ± 56
TNF-a (pg/ml)
TNF-a (0) 3.8 (3.4-4.9) 3.8 (3.5-4.0) 3.9 (3.6-4.9) 3.6 (3.0-4.2) 3.8 (3.6-4.0) 3.9 (3.4-4.3)
TNF-a (60) 5.7 (5.1-5.9) 5.3 (5.0-5.8) 5.7 (5.4-6.1) 5.3 (5.2-5.9) 5.8 (5.5-5.9) 5.4 (5.3-6.7)
TNF-a (120) 6.4 (5.9-7.9) 6.5 (5.5-6.8) 7.5* (6.8-8.3) 6.4 (3.5-7.1) 7.6† (6.5-7.8) 6.2 (5.8-8.1)
IL-6 (pg/ml)
IL-6 (0) 2.5 (2.2-3.4) 2.5(2.3-3.1) 3.2 (2.4-3.4) 3.0 (2.3-3.5) 2.5(2.0-3.4) 3.2(2.6-3.4)
IL-6 (60) 4.2(3.7-4.9) 4.0(3.9-4.2) 4.4 (3.7-5.0) 4.3 (3.7-4.6) 4.5(3.7-5.2) 4.3(3.8-4.6)
IL-6 (120) 4.7(4.4-5.0) 4.4(3.9-4.9) 5.0 (4.4-7.2) 4.4 (3.5-5.4) 5.2(3.0-5.8) 4.8(4.3-5.0)
NT (μmol/l)
NT (0) 0.23 (0.12-0.24) 0.17 (0.15-0.23) 0.17 (0.14-0.23) 0.18 (0.04-0.25) 0.20 (0.18-0.23) 0.17 (0.14-0.18)
NT (60) 0.34 (0.21-0.36) 0.33 (0.25-0.35) 0.33 (0.28-0.38) 0.35 (0.16-0.36) 0.35 (0.31-0.39) 0.29 (0.26-0.37)
NT (120) 0.92 (0.65-1.02) 0.84 (0.72-0.87) 0.98* (0.80-1.19) 0.88 (0.76-0.98) 1.02† (0.85-1.27) 0.87 (0.79-1.16)
Data are displayed in mean ± SD or median (interquartile range); *p < 0.05 represents the significant differences between normal and CAD in IGT group; †P <
0.05 represents the significant differences between normal and CAD in T2DM group; IL-6: interleukin-6; NT: nitrotyrosine; PG: plasma glucose; TNF-a: tumor
necrosis factor-alpha
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strated with the 2-hr levels of TNF-a (r = 0.195, P <
0.05) and nitrotyrosine (r = 0.352, P < 0.05), but not IL-
6. There were no significant correlations of postchal-
lenge TNF-a, IL-6 or nitrotyrosine levels at 2-hr with
age, fasting glucose, hemoglobin A1C, traditional cardio-
vascular risk factors and lipid profiles.
Odds ratios of CAD risk by quartiles of postchallenge
proinflammatory and nitrosative cytokines
The crude and adjusted odds ratios of CAD risk accord-
ing to quartiles of postchallenge TNF-a, IL-6 and nitro-
tyrosine, respectively, at 120 minutes after 75 g-OGTT
by logistic regression analysis are shown in Table 4.
Unadjusted TNF-a (120) level in 4
th quartile was
significantly associated with CAD (OR: 2.5, 95% CI, 1.3-
6.9; P < 0.05). Unadjusted nitrotyrosine (120) levels in
3
rd (OR: 2.7, 95% CI, 1.7-4.5) and 4
th q u a r t i l e s( O R :4 . 9 ,
95% CI, 2.7-8.6) were both significantly predictors of
CAD (both P values < 0.05). After adjustments for age,
sex, body mass index, blood pressure, hemoglobin A1C,
lipid profiles and GT status, nitrotyrosine (120) levels in
4
th quartiles (OR: 3.1, 95% CI, 2.2-5.3; P <0 . 0 5 )
remained as a powerful predictor of CAD.
Discussion
The major findings in this study were as follows: firstly,
postchallenge hyperglycemia can rapidly elicit circulating
TNF-a, IL-6 and nitrotyrosine levels after 75 g-OGTT
in all patients regardless of glucose tolerance status or
Figure 3 Box and whisker plots of PG, TNF-a, IL-6 and nitrotyrosine levels at 2-hr after 75 g-OGTT. Each plot indicates the median
(middle bar in rectangle), 10
th (bottom of bar), 25
th (bottom of rectangle), 75
th (top of rectangle), and 90
th centiles (top of bar) in patients
categorized by the presence of CAD and GT status. Patients with CAD and AbnGT have significantly higher postchallenge TNF-a and
nitrotyrosine levels at 2-hr compared to those without CAD, whereas IL-6 and glucose concentrations are not significantly different either in
patients with NGT or AbnGT. *p < 0.05 by Kruskal-Wallis test followed by Mann- Whitney U test with Bonferroni correction.
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patients with AbnGT were more likely to have CAD,
there were no significant differences of postchallenge
hyperglycemia ranging from PG-0 to PG-120 between
CAD and non-CAD patients in either NGT or AbnGT
groups. Thirdly, postchallenge TNF-a and nitrotyrosine
levels at 2-hr, rather than hyperglycemia per se,w e r e
associated with the presence of CAD. Finally, after
adjusting traditional cardiovascular risk factors and glu-
cose tolerance status, nitrotyrosine at 2-hr after 75 g-
OGTT in highest quartiles remained a powerful predic-
tor of CAD.
High prevalence of AbnGT in patients referred for
coronary arteriography
Our study results revealed that, in patients referred for
coronary arteriography with previously unrecognized
T2DM, in which only 42% of patients had NGT and
24% had newly detected T2DM. This finding was con-
sistent with previous reports that higher prevalence of
AbnGT, ranging from 50% ~ 60%, can be found in
patients referred for coronary angiography despite of
excluding T2DM patients or those with fasting PG >
126 mg/dl (7.0 mmol/l) [21-23]. In contrast, in a recent
cross-sectional population-based study with over 15,000
non-diabetes patients enrolled, the overall prevalence of
AbnGT was approximately 5.6% [24]. In the DECODE
study, more than half of diabetic patients had only iso-
lated postchallenge hyperglycemia and three quarters of
patients with IGT had normal fasting glucose [5]. In our
study, 54% (22 of 41) of patients with IGT and 24% (7
of 29) of patients with T2DM were categorized as hav-
ing normal fasting glucose. Since several epidemiological
studies have indicated that subjects with prediabetic
conditions have a raised risk of cardiovascular diseases,
early identification of these patients is very important
[5,6,25].
Beyond postchallenge hyperglycemia
In this study, patients with AbnGT were more likely to
have CAD or higher numbers of stenosed coronary
arteries than those with NGT. However, in comparison
between patients with CAD and non-CAD, there were
no significant differences among PG-0 to PG-120 during
75 g-OGTT and the PG response curves were almost
identical to each other in both NGT and AbnGT
groups. Controversial results regarding the correlations
of postchallenge hyperglycemia with CAD could be
Table 4 Odd ratios of CAD to quartiles of TNF-a, IL-6 and nitrotyrosine after 75 g OGTT at 120 minutes
Quartiles
P value‡
Characteristics 1 2 3 4
TNF-a (120) (pg/ml) < 6.0 6.0-6.8 6.8-7.6 > 7.6
No. of CAD 13 16 15 21
No. of Non-CAD 15 20 9 11
Crude OR 1.0 1.3 (0.7-2.3) 1.5 (0.8-4.5) 2.5 (1.3-6.9)* < 0.05
Adjusted OR† 1.0 1.2 (0.5-2.1) 1.4 (0.7-3.1) 1.9 (0.9-3.3) 0.053
Quartiles
P value‡
12 3 4
IL-6 (120) (pg/ml) < 4.0 4.0-5.0 5.0-5.5 > 5.5
No. Of CAD 14 15 13 23
No. of Non-CAD 18 22 10 5
Crude OR 1.0 1.1 (0.9-2.6) 1.5 (0.7-3.5) 1.9 (0.9-4.2) 0.078
Adjusted OR† 1.0 1.2 (0.8-2.1) 1.3 (0.8-2.9) 1.5 (0.7-3.9) 0.121
Quartiles
P value‡
12 3 4
NT (120) (μmo/l) < 0.70 0.70-0.90 0.91-1.10 ≧ 1.10
No. Of CAD 4 22 17 22
No. of Non-CAD 7 23 16 9
Crude OR 1.0 1.5 (0.9-2.6) 2.7 (1.7-4.5)* 4.9 (2.7-8.6)* < 0.01
Adjusted OR† 1.0 1.2 (0.7-2.1) 1.7 (0.8-3.6) 3.1 (2.2-5.3)* < 0.05
*P values < 0.05. Crude odd ratios (ORs) and confidence intervals (CIs) were calculated using logistic regression models comparing risk of each of the upper 3
quartiles for a given parameter to the lowest quartile. † Adjusted for age, gender, body mass index, smoking, lipid profiles, medication and glucose tolerance
status by conditional logistic regression analysis. ‡P values for trend across quartiles
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postchallenge hyperglycemia was independently asso-
ciated with the numbers of diseased coronary arteries
[26], which was not found in the study reported by
Satoh et al. [23]. On the other hand, Takezako et al.
reported that glucose response did not correlate with
the severity of coronary atherosclerosis [27]. Accord-
ingly, postchallenge hyperglycemia might not consis-
tently be the only responding factor that causes
cardiovascular disease. Instead, it should be considered
also as a marker of underlying metabolic abnormalities
[9]. These findings from our study highlight the impor-
tance of postchallenge proinflammatory and nitrosative
stress responses, rather than postchallenge hyperglyce-
mia per se, in associations with coronary atherosclerosis
in patients without previously diagnosed T2DM.
Postchallenge proinflammatory and nitrosative responses
versus CAD
Most of previous clinical studies reported the baseline
levels of inflammatory biomarkers (e.g., C-reactive pro-
tein, fibrinogen) and their correlations with postchal-
lenge hyperglycemia or glucose tolerance status after 75
g-OGTT, with or without coronary angiographic data
for further discussion about the presence of CAD
[28-31]. Esposito et al. have shown that consecutive
pulses of intravenous glucose could increase circulating
TNF-a and IL-6 to a greater extent than during similar
and stable glycemic levels, and this effect was more pro-
nounced in subjects with IGT and can be blocked by
anti-oxidant [14]. Ceriello et al. demonstrated that post-
prandial hyperglycemia can induce oxidative stress by
generation of nitrotyrosine independently and cumula-
tively in healthy subjects and T2DM patients, but
patient with IGT were not included in their study
[17,32]. The present study clearly collaborates and
extends their findings into patients with IGT, indicating
that postchallenge proinflammatory and nitrosative
stress responses might be more powerfully correlated to
the presence of coronary atherosclerosis than their cor-
responding levels at baseline.
Although TNF-a, IL-6 and nitrotyrosine can all be eli-
cited time-dependently after 75 g-OGTT, the 2-hr IL-6
levels failed to discriminate the presence of absence of
CAD in patients with IGT or T2DM. Nevertheless, it
was noteworthy that IL-6 levels at 2-hr were signifi-
cantly higher in patients with triple-vessel diseases com-
pared with those non-CAD patients regardless of GT
status in our study. The potential roles of IL-6 on cardi-
ovascular risk had been postulated in patients with
T2DM and unstable CAD [33,34], but the changes of
IL-6 had ever been reported poorly correlated to insulin
sensitivity in patients with AbnGT [35]. Postchallenge
TNF-a and nitrotyrosine levels at 2-hr were significantly
higher in patients with CAD and also significantly asso-
ciated with 2-hr PG. Moreover, in logistic regression
analysis after adjusting traditional risk factors and GT
status, 2-hr nitrotyrosine levels remained the robust pre-
dictor for the presence of CAD in our study. Our find-
ings might not only offer the explanation to the
exponential relationship between 2-hr postchallenge glu-
cose levels and the incidence of cardiovascular disease
in subjects with IGT from meta-analysis,
2 but also indi-
cate that the hyperglycemia-induce atherosclerotic
changes were mostly correlated to oxidative stress
responses. Meanwhile, the changes of TNF-a might be
better and earlier than those of IL-6 in predicating CAD
during postchallenge hyperglycemia in patient with
AbnGT.
Association of CAD between NGT and AbnGT: the
discrepancy
In our study, significant differences of postchallenge 2-
hr nitrotyrosine and TNF-a were identified between
CAD and non-CAD patients in AbnGT group, but not
in the NGT patients. The possible explanation to this
discrepancy might be that both time and level of peak
of glucose response curve in the present study tended to
be earlier (at 30-60 minutes) and lower in the NGT
patients, compared to patients with AbnGT (60-90 min-
utes) [29]. Similar findings can also be found in the
postchallenge response curves of PG or nitrotyrosine
after 75 g-OGTT inT2DM and normal control subjects
in the other studies [20,24]. The results of early and
lower hyperglycemia spike found in NGT patients might
render relative insufficient impacts of these postchal-
lenge proinflammatory and nitrosative stress responses
to produce sustained effects upon coronary athero-
sclerotic changes. In addition, it is widely accepted
patients with IGT represented more advanced glycemic
disorders compared to those NGT patients with insulin
resistance but compensatory insulin production [4,33].
Accordingly, postchallenge hyperglycemia-induced
proinflammatory cytokines and nitrosative changes on
CAD might be been more significantly associated with
CAD in patients with AbnGT, but less in patients with
NGT.
Study limitations
This study had several limitations. First, the postchal-
lenge responses of insulin and insulin resistance esti-
mated by homeostasis model assessment (HOMA-IR)
were not included in this study. The associations with
insulin resistance with the proinflammatory responses
and nitrosative stress might need further studies to
address. Second, the number of patients in our study
was still relatively small. The difference of glucose para-
meters and IL-6 after 75 g-OGTT might become
Chu et al. Cardiovascular Diabetology 2012, 11:21
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ever, TNF-a and nitrotyrosine induced by postchallenge
hyperglycemia reached statistical significance in our
study. Third, the atherosclerotic plaque burden of cor-
onary arteries in our study might be still underestimated
by using clinical CAD scoring. Further investigations of
coronary atherosclerotic plaque burden evaluated by
new imaging modalities, e.g. coronary intravascular
ultrasound or mutli-slices computer tomography, to cor-
relate the coronary plaque burden with postchallenge
proinflammatory and nitrosative stress responses after
acute hyperglycemia might also be warranted.
Conclusions
High prevalence of AbnGT is demonstrated in patients
without previously recognized T2DM referred for cor-
onary angiography. In patients with AbnGT, even under
the identical postchallenge hyperglycemia levels, the
dynamically postchallenge responses TNF-a and nitro-
tyrosine are significantly associated with the presence of
CAD. Our findings highlight the importance in surveil-
lance of these postchallenge proinflammatory and nitro-
sative stress biomarkers by 75 g-OGTT for diagnostic
and therapeutic assessments of CAD risks in patients
without previously recognized T2DM.
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